Mission

Cancer is a disease of many faces. A major challenge with this disease is treatment failure, which may occur as a result of intrinsic tumour-cell properties, or the emergence of drug-resistant clones following drug selection pressure. Through the collaborative use of omics profiling, imaging, molecular biology, pharmacology and in silico approaches, we seek to (1) define the mechanisms by which tumours respond to treatment, and (2) design therapeutic strategies that maximise tumour kill with minimal host toxicity.